These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 30333065)

  • 1. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
    Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
    J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study.
    Ishihara H; Kondo T; Takagi T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Tanabe K
    Target Oncol; 2018 Oct; 13(5):611-619. PubMed ID: 30232691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.
    Herrmann T; Ginzac A; Molnar I; Bailly S; Durando X; Mahammedi H
    Cancer Med; 2021 Oct; 10(19):6705-6713. PubMed ID: 34405573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study.
    Işık D; Kınıkoğlu O; Akdağ G; Altıntaş YE; Türkoğlu E; Yildirim S; Sürmeli H; Başoğlu T; Odabaş H; Turan N
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064516
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma.
    Ishihara H; Tachibana H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Target Oncol; 2019 Aug; 14(4):453-463. PubMed ID: 31359231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab.
    Beulque Y; Kinget L; Roussel E; Mobaraki S; Laenen A; Debruyne PR; Van Herck Y; Baldewijns M; Wozniak A; Garg AD; Zucman-Rossi J; Couchy G; Albersen M; De Wever L; Haaker L; Beuselinck B
    Acta Oncol; 2024 Aug; 63():658-668. PubMed ID: 39129249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 13. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?
    Ocak B; Sahin AB; Ertürk I; Korkmaz M; Erdem D; Cakıroglu U; Karaca M; Dirican A; Olmez OF; Goktas Aydın S; Gökyer A; Kücükarda A; Gülmez A; Yumuk PF; Demircan NC; Oyman A; Sakalar T; Karatas F; Demir H; Yasin AI; Deligonul A; Dakiki B; Goktug MR; Avcı O; Tacar SY; Turhal NS; Deniz GI; Kacan T; Cubukcu E; Evrensel T
    Curr Oncol; 2024 Sep; 31(9):5195-5205. PubMed ID: 39330012
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
    Brown LC; Desai K; Wei W; Kinsey EN; Kao C; George DJ; Rini BI; Ornstein MC; Zhang T
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
    Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
    Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.
    Nishiyama N; Hirobe M; Kikushima T; Matsuki M; Takahashi A; Yanase M; Ichimatsu K; Egawa M; Hayashi N; Negishi T; Masumori N; Kitamura H
    BMC Urol; 2020 Jul; 20(1):110. PubMed ID: 32711491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
    Escudier B; Motzer RJ; Sharma P; Wagstaff J; Plimack ER; Hammers HJ; Donskov F; Gurney H; Sosman JA; Zalewski PG; Harmenberg U; McDermott DF; Choueiri TK; Richardet M; Tomita Y; Ravaud A; Doan J; Zhao H; Hardy H; George S
    Eur Urol; 2017 Sep; 72(3):368-376. PubMed ID: 28410865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.
    José JM; Jose M; Silverio R; Federico V; Isabel C; Martin OA; Inmaculada B; Cristina C; Julia HC; Dolores TM; Jose G; Paola P; Nieves DP; Vicent A; Sara B; Sara M; Julián L; Manuel S; Del Carmen MM; Ángel CM; Vicente G
    Clin Transl Oncol; 2020 Sep; 22(9):1517-1523. PubMed ID: 32048159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.